Form 4: Beta Bionics Director Acquires Stock Options
SEC Form 4 Filing
Maria Palasis, a director at Beta Bionics, acquired stock options for 9,137 shares of common stock on January 31, 2025.
Summary
- Maria Palasis, a director at Beta Bionics, was granted stock options to purchase 9,137 shares of common stock.
- The options were granted on January 31, 2025, at an exercise price of $7.51 per share.
- The options vest in 36 equal monthly installments starting from August 15, 2022.
- The options expire on January 24, 2033.
- The shares underlying the options were converted from Class B Common Stock to Common Stock prior to the company's initial public offering.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of stock options to a director, which is generally a positive sign of alignment between management and shareholders. It is not a major event, but it is a normal and expected part of corporate governance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire or dispose of company securities. It is a routine part of corporate governance and transparency.
Comparison to Industry Standards
- Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, to align their interests with those of shareholders.
- The vesting schedule of 36 months is also a typical arrangement to incentivize long-term commitment.
- The exercise price of $7.51 is a specific value for this grant and would need to be compared to other grants at the company and in the industry to determine if it is standard.
Stakeholder Impact
- The stock option grant could have a minor positive impact on shareholder sentiment as it indicates director alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 2022-08-15 | Start date for the monthly vesting of the stock options. |
| 2025-01-31 | Date the stock options were granted to the director. |
| 2033-01-24 | Expiration date of the stock options. |
| 2025-02-03 | Date the form was signed. |
Keywords
stock options, director, insider trading, beneficial ownership, Beta Bionics, BBNX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.